Core Viewpoint - The company, Yidu Tech (02158), demonstrates strong confidence in its long-term value and the prospects of the AI healthcare industry through its recent share buyback activities, totaling over 76 million HKD this year [1] Group 1: Share Buyback Activities - On February 27, Yidu Tech repurchased 322,000 shares at approximately 5.99 HKD per share, with a total expenditure of nearly 2 million HKD [1] - The company has completed 19 buybacks this year, reflecting its commitment to enhancing shareholder value [1] Group 2: Industry Trends - A report from Zhonghang Securities highlights that domestic and international healthcare companies are increasingly investing in AI products and services across various sectors, including medical imaging, clinical decision support, precision medicine, health management, medical information technology, drug development, and medical robotics [1] - AI is evolving from a "technical assistance" role to becoming a core driver of "value reshaping" and "efficiency revolution" in the healthcare industry, with its commercial value penetrating various stages from research to clinical, payment, and patient levels [1] Group 3: Business Developments - Yidu Tech has made significant innovations, including the internal testing of its clinical evidence-based intelligent system, "Yidu Zhixun" [1] - The company's project for infectious disease monitoring and early warning in Hainan Free Trade Port has been recognized at the national level, being included in the "2025 Data Element ×" competition award project case collection [1]

Group 1 - The company, Yidu Tech (02158), announced a share buyback on February 27, 2026, spending HKD 1.9273 million to repurchase 322,000 shares at a price range of HKD 5.93 to 6 per share [1]

Group 1 - The company, Yidu Tech (02158.HK), announced a share buyback on February 27, spending HKD 1.927 million to repurchase 322,000 shares [1]

Core Viewpoint - The company, Yidu Tech (02158), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will repurchase 322,000 shares at a total cost of HKD 1.9273 million [1] - The buyback price per share ranges from HKD 5.93 to HKD 6 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年2月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Core Viewpoint - The company, Yidu Tech (02158), continues to demonstrate confidence in its development and the AI healthcare sector through ongoing share buybacks, totaling over HKD 74 million since January 26, 2023 [1] Group 1: Share Buyback Activity - On February 26, Yidu Tech repurchased 382,000 shares at approximately HKD 5.97 per share, with a total expenditure of nearly HKD 2.3 million [1] - The company has completed 18 buybacks this year, reflecting a strong commitment to enhancing shareholder value [1] Group 2: Business Innovations and Developments - Yidu Tech's "Yidu Zhixun" clinical evidence-based intelligent system has entered the internal testing phase, aimed at meeting the real needs of clinical doctors and medical researchers [1] - The company is inviting frontline clinical doctors to participate in the experience and co-creation of this mini-program [1] Group 3: Recognition and Projects - The "Hainan Free Trade Port 'External Prevention of Input' Infectious Disease Monitoring and Early Warning" project, led by the Hainan Provincial Health Commission's Statistical Information Center with core technical support from Yidu Tech, was recognized as an excellent practice case in the healthcare sector [1]

Core Viewpoint - Yidu Tech (02158) announced a share buyback plan, intending to repurchase 382,000 shares at a total cost of HKD 2.2802 million on February 26, 2026 [1] Group 1 - The company plans to execute the buyback to enhance shareholder value [1] - The total amount allocated for the buyback is HKD 2.2802 million [1] - The number of shares to be repurchased is 382,000 [1]

Group 1 - The company, Yidu Tech (02158.HK), announced a share buyback on February 26, spending HKD 2.28 million to repurchase 382,000 shares [1]

Group 1 - The company, Yidu Tech (02158), announced a share buyback plan on February 26, 2026, involving an expenditure of HKD 2.2802 million to repurchase 382,000 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年2月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存 ...